Muscle Pharm Corporation (MSLPQ)

[CWS1987]

The resignations are pretty puzzling. Not only does it seemingly not increase the number of independent directors, but the departure of Andrew Lupo, in particular, is concerning. He was the head of the compensation committee, but given his background in corporate compliance, I got the impression he was brought in at least in part to help clear up the SEC investigation. I'm struggling to determine if his departure is a good thing (the SEC investigation is more of a done deal than the company is letting on) or a bad thing (he pushed for more responsible compensation and was told to take a hike). I would be interested to hear other people's ideas on the move.